Opinion on Pharmaceuticals and Healthcare in Germany

Published within

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Colorectal cancer: prevalence to rise 2.7% in Italy

Published By Datamonitor
18 Jun 2002
ResearchWire
ResearchWire

Diabetic neuropathy: 2.2 million cases in Germany

Published By Datamonitor
19 Jun 2002
ResearchWire
ResearchWire

Prostate cancer: incidence rate will reach 326,000 by 2010

Published By Datamonitor
25 Jun 2002
ResearchWire
ResearchWire

HIV: 850,000 sufferers in US

Published By Datamonitor
28 Jun 2002
CommentWire
CommentWire

Anadys: hepatitis C grant should boost research

The German government has awarded US-based biotech company Anadys a grant to identify proteins involved in hepatitis C transmission. Anadys' novel approach to drug development could well result in the development of more effective products, which would enhance the company's position in the anti-infectives field.

Published By Datamonitor
02 Jul 2002
CommentWire
CommentWire

Schering AG: harvesting the benefits

Schering AG's June sale of its Aventis CropScience stake has provided a E1.5 billion cashpile, which the company is investing in its pharma business. Two deals completed in the last week should boost the German firm's profile as an innovative biotech-focused pharma company, driving near-double-figure annual growth for the next five years.

Published By Datamonitor
03 Jul 2002
CommentWire
CommentWire

MorphoSys/Roche: antibody hopes for Alzheimer's

German biotech MorphoSys and its partner Roche have achieved a key milestone in discovering a series of antibodies to treat CNS disorders such as Alzheimer's disease. While there are still serious technical and clinical challenges ahead, this innovative new development is certainly good news for Europe's biotechnology sector.

Published By Datamonitor
10 Jul 2002
ResearchWire
ResearchWire

Leukemia: incidence to reach 74,460 in 2010

Published By Datamonitor
23 Jul 2002
CommentWire
CommentWire

GSK/Bayer: vardenafil closer to challenging Viagra

Pfizer's Viagra has monopolized the erectile dysfunction market, but will face competition from GSK/Bayer's vardenafil and Lilly's Cialis when these drugs launch in 2003. Whether the challengers will take substantial market share from Viagra, however, depends on whether GSK and Lilly can persuade physicians and consumers that they offer significant advantages.

Published By Datamonitor
26 Jul 2002
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

No help is available.